Abstract
The effectiveness of cabergoline in 50 men with psychogenic erectile dysfunction was investigated in a 4-month, randomized, placebo-controlled, double-blind study with validated psychological tests, and prolactin, follicle-stimulating hormone, luteinizing hormone and testosterone serum levels. Cabergoline treatment was well-tolerated and resulted in normalization of hormone levels in most cases. In the cabergoline-treated group, significant interactions between prolactin and testosterone serum concentrations were observed. Erectile function improved significantly. Sexual desire, orgasmic function, and the patient's and his partner's sexual satisfaction were also enhanced. Cabergoline may be an effective and safe alternative agent for men with psychogenic ED.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cavallero R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E . Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004; 65: 187–190.
Krueger THC, Haake P, Haverkamp J, Kramer M, Exton MS, Saller B et al. Effects of acute prolactin manipulation on sexual drive and function in males. J Endocrinol 2003; 179: 357–365.
Wittstock M, Benecke R, Dressler D . Cabergoline can increase penile erections and libido. Neurology 2002; 58: 831.
De Rosa M, Zarrilli S, Vitale G, Di Somma C, Orio F, Tauchmanova L et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004; 89: 621–625.
Wiltink J, Hauck EW, Phadayanon M, Weidner W, Beutel ME . Validation of the German version of the International Index of Erectile Function (IIEF) in patients with erectile dysfunction, Peyronie's disease and controls. Int J Impot Res 2003; 15: 192–197.
Muellner M . Evidence based medicine. Springer: Wien, New York, 2002.
Hamilton M . Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1976; 6: 278–296.
Hamilton M . The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–55.
Schulz P, Scholtz W, Becker P . Trier Inventory for the Assessment of Chronic Stress. Goettingen: Hogrefe, 2004.
Mac Donagh R, Ewings P, Porter T . The effect of erectile dysfunction on quality of life: psychometric testing of a new quality of life measure for patients with erectile dysfunction. J Urol 2002; 167: 212–217.
Glick HA, McCarron TJ, Althof SE, Corty EW, Willke RJ . Construction of scales for the Center for Marital and Sexual Health (CMASH). Sexual Functionning Questionnaire. J Sex Marital Ther 1997; 23: 103–117.
De Rosa M, Zarrilli S, Di Sarno A, Milano N, Gaccione M, Boggia B et al. Hyperprolactinemia in men. Endocrine 2003; 20: 75–82.
Hull EM, Lorrain DS, Du J, Matuszewich L, Lumley LA, Putnam SK et al. Hormone-neurotrasmitter interactions in the control of sexual behavior. Behav Brain Res 1999; 105: 105–116.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nickel, M., Moleda, D., Loew, T. et al. Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study. Int J Impot Res 19, 104–107 (2007). https://doi.org/10.1038/sj.ijir.3901483
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901483